ClinicalTrials.gg
TerminatedNCT00743470Updated Nov 2, 2010

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

A Phase 1 interventional study of lopinavir/ritonavir and rifabutin in HIV and Tuberculosis, sponsored by Abbott. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-02.

Sponsored by Abbott · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing rifabutin in Tuberculosis — none open to participants now, none under way, none of them phase 3. Rifabutin · Tuberculosis.

Enrollment
11th of 12
15 · median 44
Started
2008
the only one that year
Phase 1
3 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Abbott

Among the 13 studies testing rifabutin in Tuberculosis, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1, and was the 7th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

None of the 13 studies testing rifabutin in Tuberculosis is open now. The open studies under Tuberculosis, anywhere →

About rifabutin

Rifabutin: first FDA approval 1992 (MYCOBUTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing rifabutin in Tuberculosis as a file.
02

Study summary

The purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.

03

Conditions studied

  • HIV
  • Tuberculosis

Browse trials for

Keywords

  • HIV co-infected with tuberculosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Male or Female 18-55 yrs.
  • Subject has provided written consent.
  • Subject is in general good health.
  • If female, subject is .
  • If female, subject is not pregnant and is not breast-feeding.
  • Subject must use methods or be surgically sterile.

Exclusion criteria

Exclusion Criteria:

  • Subject is HAV-IgM, or Ab positive.
  • Positive screen for drugs of abuse, alcohol, or smoking.
  • Cannot be on any medication, including over the counter drugs.
  • Cannot have previous history of alcohol or drug abuse.
  • Cannot have history of any major diseases or disorders.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    A, B

    Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.

    Drug: lopinavir/ritonavir · Drug: rifabutin

  • Experimental
    C

    Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.

    Drug: lopinavir/ritonavir · Drug: rifabutin

Interventions

  • Druglopinavir/ritonavir

    lopinavir/ritonavir tablet; see arm for intervention description

    Also known as: ABT-378, Kaletra

  • rifabutin capsule; see arms for intervention description

06

What researchers measure

Primary outcomes

  1. Analysis of pharmacokinetic variables will be computed for each sampling time and each parameter.

    Time frame: Approximately 0.5 - 1 month

  2. Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.

    Time frame: Approximately 0.5 - 1 month

07

Study locations

1 site
  • Site Reference ID/Investigator# 11441
    Waukegan, Illinois 60085, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2008
First posted
Aug 28, 2008
Start
Aug 2008
Primary completionActual
Oct 2008
Last update
Nov 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00743470
Lead sponsor
Abbott
First posted
Aug 28, 2008
Start date
Aug 2008
Primary completion
Oct 2008
Last update
Nov 2, 2010

Study contacts

Angela Nilius, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifabutin

Start the discussion